BioCentury | Sep 30, 2020
Product Development

Ovid looks to broad path forward for rare epilepsy program

Three years after striking a deal with Takeda to take the lead on developing the Japanese pharma’s soticlestat, Ovid is considering multiple paths to market for the therapy in rare epileptic encephalopathies.  On Wednesday, Ovid...
BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

A Phase III readout that boosted Marinus’ value on Tuesday is the first in a series of upcoming milestones that could lead to the company carving out a commercial niche in rare seizure disorders. Trial...
BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

Concarlo is developing targeted therapies for metastatic breast cancer that take aim at both CDK4/6-driven cell proliferation and CDK2-driven drug resistance in one go.  The company spun out of SUNY...
BioCentury | Aug 25, 2020
Finance

$155M Perceptive-led note deal enables Kronos to fund newly acquired Gilead asset’s pivotal trial

After acquiring a Phase III-ready asset from Gilead last month, Kronos raised $155 million on Monday to fund the cancer therapy’s registrational trial, slated for 2021. The funding will also enable Kronos, led by Gilead...
BioCentury | Aug 18, 2020
Product Development

Gilead, Tango expand cancer partnership; plus Roche approval, Novavax COVID-19 efficacy study and G1, Myovant and PTC applications under review

Gilead takes stake in Tango, expands 2018 dealGilead Sciences Inc. (NASDAQ:GILD) million has expanded its 2018 deal with Tango Therapeutics Inc. to cover worldwide options over seven years from five to 15 immuno-oncology targets in exchange...
BioCentury | Jul 31, 2020
Finance

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 24, 2020
Finance

Olema aims to deploy $54M round to carve its niche in breast cancer

Olema’s plans for its oral selective estrogen receptor degrader attracted a crossover-laden syndicate to the San Francisco company’s $54 million series B round. Olema plans to take the therapy, which is administered daily, into a...
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

David Meeker will become president and CEO of obesity company Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) while remaining chairman, a title he’s held since 2017. He succeeds CFO Hunter Smith, who was serving as president and CEO...
BioCentury | Jul 17, 2020
Deals

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition...
Items per page:
1 - 10 of 712